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Abstract
Background: In Madagascar, the multidrug-resistant tuberculosis (MDR-TB) surveillance programme was launched
in late 2012 wherein previously treated TB cases and symptomatic MDR-TB contacts (hereafter called presumptive
MDR-TB cases) undergo drug susceptibility testing. This retrospective review had per aim to provide an update on
the national MDR-TB epidemiology, assess and enhance programmatic performance and assess Madagascar’s MDR-
TB cascade of care.
Methods: For 2012–2017, national TB control programme notification, clinical management data and reference
laboratory data were gathered. The development and coverage of the surveillance programme, the MDR-TB
epidemiology and programmatic performance indicators were assessed using descriptive, logistic and spatial
statistical analyses. Data for 2017 was further used to map Madagascar’s TB and MDR-TB cascade of care.
Results: The geographical coverage and diagnostic and referral capacities of the MDR-TB surveillance programme
were gradually expanded whereas regional variations persist with regard to coverage, referral rates and sample
referral delays. Overall, the rate of MDR-TB among presumptive MDR-TB cases remained relatively stable, ranging
between 3.9% in 2013 and 4.4% in 2017. Most MDR-TB patients were lost in the second gap of the cascade
pertaining to MDR-TB cases reaching diagnostic centres but failing to be accurately diagnosed (59.0%). This poor
success in diagnosis of MDR-TB is due to both the current use of low-sensitivity smear microscopy as a first-line
diagnostic assay for TB and the limited access to any form of drug susceptibility testing. Presumptive MDR-TB
patients’ sample referral took a mean delay of 28 days before testing. Seventy-five percent of diagnosed MDR-TB
patients were appropriately initiated on treatment, and 33% reached long-term recurrence-free survival.
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Conclusions: An expansion of the coverage and strengthening of MDR-TB diagnostic and management capacities
are indicated across all regions of Madagascar. With current limitations, the surveillance programme data is likely to
underestimate the true MDR-TB burden in the country and an updated national MDR-TB prevalence survey is
warranted. In absence of multiple drivers of an MDR-TB epidemic, including high MDR-TB rates, high HIV infection
rates and inter-country migration, Madagascar is in a favourable starting position for MDR-TB control and
elimination.
Keywords: Cascade of care, Drug susceptibility testing, Epidemiology, Madagascar, Multidrug-resistant tuberculosis,
Surveillance
Background
Madagascar exemplifies some of the main challenges in tu-
berculosis (TB) and multidrug-resistant TB (MDR-TB) sur-
veillance. Nationally representative data on MDR-TB date
back to the first and only national drug resistance survey
conducted in 2005–2006. At that time, the MDR-TB rate
was 0.2% among new cases (i.e. primary resistance) and 3.4%
among previously treated cases (including secondary resist-
ance) [1]. In 2018, according to World Health Organization
(WHO) estimates, the combined rates of MDR-TB and
rifampicin-resistant TB had reached 0.5% for primary and
5.9% for secondary resistance, leading to a total incidence of
1.6/100,000 population [2]. Beyond these estimates, which
rely on sparse quantity and quality of data, the understanding
of the drug-resistant TB epidemiology in Madagascar relies
on (i) a one-time surveillance data review with limited scope
from 2014, (ii) small-scale studies focusing on urban subpop-
ulations and (iii) nationwide limited capacity for routine drug
susceptibility testing (DST), including rifampicin resistance
testing with GeneXpert MTB/RIF (Cepheid, CA, USA) [3, 4].
Therefore, surveillance of TB drug resistance in Madagascar
is lacking behind standards put forward by the WHO [5].
In September 2012, the Madagascar national TB control
programme (NTP) launched the MDR-TB surveillance
programme [4]. Within this programme, clinical samples
of presumptive MDR-TB patients—defined as previously
treated cases and symptomatic MDR-TB contacts—
undergo DST in regional or national reference laborator-
ies. The real-time surveillance of drug resistance and the
timely analysis of the wealth of paper-based data on a
quarterly basis can be a challenge for an NTP that is fo-
cusing predominantly on service delivery, such as in
Madagascar. Yet, periodic review of national drug resist-
ance data can be used to assess and enhance program-
matic performance. Tools such as geographic information
systems (GIS) that combine epidemiological, infrastruc-
tural and geospatial data enable rapid visualisation and
understanding of disease epidemiology and programme
development in terms of coverage and referral rates [6, 7].
The cascade of care approach has become another useful
tool helping countries to comprehensively exploit national
data and visualise deficiencies at every step of a patients’
pathway to cure [8]. In India and South Africa, this ap-
proach has identified and quantified gaps in TB case de-
tection, case holding and disease outcome and thus
supported the formulation of priority interventions [9, 10].
Here, we used NTP data from 2012 to 2017 and ap-
plied GIS and cascade of care approaches to (i) describe
the infrastructures and processes of Madagascar’s MDR-
TB surveillance programme, (ii) assess its deployment in
space and time, (iii) measure key laboratory pre- and
post-analytic performance indicators, (iv) provide an up-
date on the national MDR-TB epidemiology and (v) as-
sess Madagascar’s TB and MDR-TB cascade of care for
2017.
Methods
Ethical considerations
Data was collected as part of Madagascar’s NTP routine
health information system under national public health law.
Data was anonymised and aggregated precluding identifica-
tion of patients at individual level. No patient informed
consent or ethical review board evaluation was warranted.
Study area
In Madagascar, with its 26 million inhabitants, some
favourable conditions for TB control prevail, including its
insular status, a low HIV prevalence and a low MDR-TB
prevalence [2, 11, 12]. However, the country is charac-
terised by several conditions favourable for ongoing TB
transmission, including (i) a weak health system, (ii) a
large proportion of the population living in rural and re-
mote areas with difficult access to healthcare, (iii) poverty
and associated factors such as overcrowding, (iv) paucity
of human resource capacities with training in TB care, (v)
low coverage of TB diagnostic and treatment facilities, (vi)
suboptimal observation of treatment and follow-up and
(vii) high prevalence of important TB risk factors, such as
undernutrition and indoor air pollution [13–15].
Case definitions and testing algorithms
According to Malagasy NTP guidelines, the WHO
reporting framework for TB and in agreement with
WHO definitions, case definitions are as follows:
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 A confirmed TB case is either a bacteriologically
confirmed (smear microscopy, GeneXpert MTB/RIF,
culture) or clinically diagnosed case.
 A presumptive MDR-TB case is defined as (i) a pre-
viously treated TB case (i.e. disease relapse, treat-
ment failure and retreatment patients according to
WHO definitions) or (ii) a symptomatic MDR-TB
contact [16].
 A confirmed MDR-TB case is a bacteriologically
confirmed TB case with laboratory confirmation of
drug resistance to rifampicin and isoniazid [16]. In
case of discrepancies between DST methods,
culture-based DST is used as the gold standard.
In Madagascar, within the MDR-TB surveillance
programme, only clinical samples of presumptive MDR-
TB patients undergo DST. Two different diagnostic algo-
rithms were sequentially implemented during the study
period (Additional file 1: Fig. S1 and Additional file 2:
Fig. S2) [4, 17, 18]. Based on these algorithms, samples
submitted for reference testing within the programme
between 2012 and 2017 were tested on phenotype DST
for first-line drugs, on GeneXpert MTB/RIF for rifampi-
cin resistance and on a combination of phenotype and
line probe assay (HAIN LifeSciences, Nehren, Germany)
for second-line drugs. As a consequence of the slightly
differing algorithms, second-line phenotypic and Geno-
type MTBDR™ line probe assay results were not available
for all included samples.
Data collection
Data was collected for the period between September
2012 and December 2017. First, the NTP organisation,
infrastructures, development of the geographical cover-
age over time and the overall implementation, including
major events that could have influenced programmatic
performance, were documented with the NTP staff and
personnel of the national reference laboratory through
interviews. Second, aggregated case notification and clin-
ical management data of all TB diagnostic and treatment
centres across Madagascar were obtained from the NTP
in digital form. This included total number of reported
TB cases as well as presumptive MDR-TB cases. Third,
diagnosis and DST data were obtained from Madagas-
car’s national reference laboratory for mycobacteria
(NRLM). Situated in the capital city of Antananarivo
and hosted by the Institut Pasteur de Madagascar, this is
the country’s only laboratory with DST capacity beyond
GeneXpert MTB/RIF testing. Data included patients’ age
and gender, TB clinical presentation, indication for DST,
geographic location of the referring diagnostic and treat-
ment centre, Löwenstein-Jensen and MGIT™ (Beckton
Dickenson, Franklin Lakes, NJ, USA) phenotyping, Gen-
eXpert MTB/RIF and first- and second-line Genotype
MTBDR™ line probe assay results. Finally, the NTP
MDR-TB clinical management data provided patient
data on treatment regimen, treatment duration, per
treatment microbiologic control testing, treatment out-
come and HIV status.
Data analysis
Quantitative (e.g. NTP notification data) and qualitative
(e.g. interviews, algorithms) data were combined to de-
scribe the nature and reconstruct the historic develop-
ment of the MDR-TB surveillance programme. A GIS was
built with ArcGIS version 10.4.1 (ESRI; Meudon Cedex,
France) using the geographical database of the
Madagascar Ministry of Public Health and administrative
boundaries of the regions available through the Office for
the Coordination of Humanitarian Affairs website. Loca-
tion of MDR-TB surveillance programme infrastructures,
including year of implementation, and multidrug-
resistance surveillance data by year and region of origin of
patients were integrated into the GIS to map the develop-
ment of the implementation of the MDR-TB surveillance
programme.
Sample referral, transportation and testing delays be-
tween peripheral diagnosis and treatment centres and
the NRLM were compared between regions using de-
scriptive statistics, including means, standard deviations
(SDs) and 95% confidence intervals (CIs). A univariable
regression model was built using previous treatment his-
tory as primary predictor to identify risk of MDR-TB ac-
quisition among the different groups, without adjusting
for other explanatory variables.
Demographic and clinical data of all laboratory-
confirmed MDR-TB samples were aggregated. Appropri-
ate referral of sputum samples for per-treatment micro-
biologic follow-up testing among confirmed MDR-TB
cases was assessed by confronting MDR-TB patients’
data on TB diagnosis and DST from the NRLM to the
NTP MDR-TB clinical management data.
Supranational WHO data, NTP notification and clin-
ical management data, NRLM data on TB diagnosis and
DST, previously published and locally assessed labora-
tory assays’ performance characteristics and systematic
review data on the natural history of TB disease were
used to map Madagascar’s TB and MDR-TB cascade of
care for 2017 only [19, 20]. As recently proposed, the
number of patients with prevalent active disease, reach-
ing and being evaluated at TB diagnostic facilities, being
diagnosed with disease, accessing treatment, completing
treatment and achieving recurrence-free survival were
used as the specific ‘steps’ of the cascade for TB and
MDR-TB care [21]. Cascade steps, used data sources
and corresponding estimates are presented in Table 1.
In case of discrepancy between the different data
sources, investigators agreed on most reliable data
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sources to construct the cascade. All calculations, dis-
crepancies and limitations are described in detail in
Additional file 3: Appendix S3. CIs around proportions
were calculated using the modified Wald method.
All statistical analyses were performed using Stata ver-
sion 14.0 (Stata Corporation, College Station, USA).
Results
Nature and development of the MDR-TB surveillance
programme
In Madagascar, symptomatic TB patients initially self-
present to a diagnostic and treatment centre (intermedi-
ate level facility) which can diagnose TB based on smear
microscopy and can implement directly observed ther-
apy for cases of drug-susceptible TB [18, 28]. In 2017,
there were 219 TB diagnostic and treatment centres
across Madagascar (compared to 215 in 2012), translat-
ing into 0.8 centres per 100,000 habitants (Fig. 1).
From those diagnostic and treatment centres, pre-
sumptive MDR-TB patients are referred to MDR-TB
collaborative centres, i.e. referral centres for potentially
drug-resistant TB cases. Collaborative centres possess
identical laboratory infrastructure as diagnostic and
treatment centres but are accredited to collect and send
sputum samples to the nearest out of seven regional ref-
erence laboratories with GeneXpert MTB/RIF testing
capacity. Sputum samples from presumptive MDR-TB
cases are referred to the MDR-TB surveillance
programme if positive on smear microscopy or if highly
suspected clinically. At programme onset, 25 (11%) diag-
nostic and treatment centres were selected and trained
to act as MDR-TB collaborative centres. The number of
collaborative centres was rapidly increased to 37 in
2013, and as of 2017, 101 MDR-TB collaborative centres
existed, corresponding to 46% of all TB diagnostic and
treatment centres in the country [4].
Fig. 1 Development of MDR-TB surveillance programme infrastructures and referral rates of presumptive MDR-TB patients, MDR-TB surveillance
programme, Madagascar, 2012–2017. a 2012. b 2013. c 2014. d 2015. e 2016. f 2017
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The regional reference laboratories send the sputum
further to the NRLM for culture and phenotypic first- and
second-line DST, regardless of the initial molecular testing
results. In case of MDR-TB confirmation, the NRLM
communicates the result to the NTP, which in turn in-
forms the referring diagnostic and treatment centre. That
centre is then responsible for transferring the patients to
one of the country’s four MDR-TB treatment centres.
MDR-TB patients are usually hospitalised during the 6-
month intensive phase of their treatment, and thereafter,
they receive 12months directly observed treatment at
their closest diagnostic and treatment centre.
Figure 1a–f present the distribution and development
of MDR-TB collaborative centres, regional reference la-
boratories equipped with a GeneXpert MTB/RIF and
treatment centres between 2012 and 2017. The pro-
cesses within the MDR-TB surveillance programme are
presented as Additional file 4: Fig. S4.
MDR-TB surveillance programme uptake
According to NTP case notification data, referral to the
MDR-TB surveillance programme was indicated for
11,643 TB patients (i.e. presumptive MDR-TB cases) be-
tween 2012 and 2017. Thereof, an overall of 2391 pa-
tients (20.5%) were factually referred for MDR-TB
evaluation whilst an evaluation was missed for the
remaining 79.5%. Absolute number of referrals to the
MDR-TB surveillance programme increased steadily
from 20 in 2012 to 269 in 2013 and to 610 in 2017
(Fig. 2). Accordingly, the referral rate evolved from
13.3% in 2013 to 24.0% in 2014, to 24.5% in 2015, to
29.1% in 2016 and to 32.7% in 2017. Regional differences
in referral rates of presumptive MDR-TB patients by
year are displayed in Fig. 1. For some regions, no sam-
ples were referred for DST during the study period des-
pite implementation of collaborative centres.
Table 2 describes the demographic, clinical and la-
boratory information for patients enrolled in the surveil-
lance programme (i.e. presumptive MDR-TB cases). The
majority of included patients were relapse cases (61.7%),
followed by failure (13.9%) and retreatment cases
(10.2%). The majority of samples taken were for suspi-
cion of pulmonary TB (96.7%).
Sample referral delays
Sample referral delays are divided between (i) from a
diagnostic and treatment centre to a GeneXpert MTB/
RIF regional laboratory and (ii) from a GeneXpert MTB/
RIF regional laboratory to the NRLM (Fig. 3). All years
combined, it took samples a mean of 19 days (± 25 SD)
to reach a GeneXpert MTB/RIF regional laboratory and
another 9 days (± 15 SD) to reach the NRLM. Even in
Analamanga, the capital region, where the NRLM is lo-
cated, the mean sample referral delay was 15 days (± 16
SD) between 2012 and 2017 and 20 days (± 16 SD) in
2017 alone.
Monoresistant TB, MDR-TB and XDR-TB
Between 2012 and 2017, 2391 samples were received at
the NRLM and bacteria from the TB complex were con-
firmed by culture, GeneXpert MTB/RIF and/or HAIN
assays in 1968 (82.4%) of those (Table 2). DST found
Fig. 2 Absolute number of indicated and referred presumptive MDR-TB cases and associated referral rate, MDR-TB surveillance programme,
Madagascar, 2012–2017
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87.7% (1726/1968) of all isolates to be pan-susceptible
and 7.0% (139/1968) were resistant to one first-line drug.
Thereof, 5.7% were resistant to isoniazid and 1.3% to ri-
fampicin. No monoresistance to ethambutol was de-
tected whilst DST for pyrazinamid was not performed.
Isoniazid monoresistance rates fluctuated strongly be-
tween years, but there was an overall increasing trend
from 4.8 to 9.1 per 100,000 population between 2013
and 2017, as depicted in Fig. 4. The increasing trend was
less accentuated for rifampicin monoresistance. Over
2012–2017, 89 (4.5%) isolates were MDR-TB and trends
showed a relatively stable rate over the observed period.
Three cases (0.2%) were found to present a pre-XDR-TB
profile, namely being resistant to isoniazid and rifampi-
cin and fluoroquinolones (n = 3) or injectable aminogly-
cosides (n = 0). XDR-TB was not yet diagnosed in
Madagascar.
Table 3 describes MDR-TB patient characteristics.
The majority of MDR-TB patients were males (67.4%;
60/89) whereas the MDR-TB rate was similar in men
and women (3.7% and 3.8%, respectively). Overall, 2.6%
of relapse, 9.9% of failure and 1.6% of retreatment cases
for which a sample was submitted to the MDR-TB sur-
veillance programme were confirmed to be MDR-TB.
Hence, failure cases were at significant higher risk to
have MDR-TB as compared to relapse cases as they had
3.87 times higher odds of confirmed MDR-TB (95% CI
2.39–6.28).
Figure 5a–c display how increased referral and testing
rates translated into increased MDR-TB diagnosis. Fig-
ure 5a shows the pooled referral rates for 2012–2017 for
each region. Figure 5b shows the cumulative absolute
number of MDR-TB cases diagnosed in Madagascar
2012–2017 by region, and Fig. 5c shows the
Table 2 Characteristics and resistance profiles of presumptive MDR-TB patients, MDR-TB surveillance programme, Madagascar, 2012–
2017
2012 2013 2014 2015 2016 2017 Total
n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Total 20 268 488 469 536 610 2391
Gender
Male 12 (60.0) 195 (73.3) 326 (66.9) 302 (65.4) 359 (67.0) 426 (70.0) 1620 (68.1)
Female 8 (40.0) 71 (26.7) 161 (33.1) 160 (34.6) 177 (33.0) 183 (30.0) 760 (31.9)
Median age (in years ± SD) 45 ± 16.4 40 ± 13.2 40 ± 13.3 39 ± 14.4 40 ± 14.2 41 ± 14.7 40 ± 14.1
Previous treatment history
Relapse 4 (20.0) 107 (39.9) 257 (52.7) 302 (64.4) 376 (70.2) 430 (70.5) 1476 (61.7)
Failure 8 (40.0) 69 (25.8) 82 (16.8) 58 (12.4) 43 (8.0) 73 (12.0) 333 (13.9)
Retreatment 0 (0.0) 21 (7.8) 53 (10.9) 54 (11.5) 54 (10.1) 61 (10.0) 243 (10.2)
Unknown 8 (40.0) 71 (26.5) 96 (19.7) 55 (11.7) 63 (11.8) 46 (7.5) 339 (14.2)
Clinical form
Pulmonary 20 (100.0) 249 (93.6) 482 (98.8) 452 (96.6) 526 (98.1) 580 (95.2) 2309 (96.7)
Extrapulmonary 0 (0.0) 17 (6.4) 6 (1.2) 16 (3.4) 10 (1.9) 29 (4.8) 78 (3.3)
MTBC identification
MTBC 16 (84.2) 229 (85.5) 440 (90.2) 367 (78.6) 438 (81.7) 478 (78.4) 1968 (82.4)
Non-MTBC 3 (15.8) 39 (14.5) 48 (9.8) 100 (21.4) 98 (18.3) 132 (21.6) 420 (17.6)
Drug resistance profiles
Pan-susceptible 9 (56.3) 199 (86.9) 392 (89.1) 331 (90.2) 368 (84.0) 427 (89.3) 1726 (87.7)
Isoniazid monoresistance 3 (18.8) 11 (4.8) 24 (5.5) 14 (3.8) 38 (8.7) 23 (4.8) 113 (5.7)
Rifampicin monoresistance 0 (0.0) 3 (1.3) 6 (1.4) 4 (1.1) 7 (1.6) 6 (1.3) 26 (1.3)
MDR-TB 3 (18.8) 13 (5.7) 17 (3.9) 16 (4.4) 19 (4.3) 21 (4.4) 89 (4.5)
Pre-XDR-TB 0 (0.0) 1 (0.4) 1 (0.2) 1 (0.3) 0 (0.0) 0 (0.0) 3 (0.2)
XDR-TB 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Other1 1 (0.1) 2 (0.1) 0 (0.0) 1 (0.1) 6 (0.3) 1 (0.1) 11 (0.5)
Data missing for gender (n = 11), clinical form (n = 4) and MTBC identification (n = 3)
MTBC Mycobacterium tuberculosis complex, MDR-TB multidrug-resistant tuberculosis, XDR-TB extensive drug-resistant tuberculosis, SD standard deviation
1Resistances to other drugs tested: aminoglycosides, ethambutol, ofloxacin, streptomycin
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corresponding MDR-TB incidence rates per 100,000
population by region over the same time period.
Cascade of care
Madagascar’s cascade of care was constructed using a
standardised model for the 2017 period [21]. Table 1
presents the used data sources, references and corre-
sponding number of cases at every step of the cascade.
Three distinct cascades were build: TB all forms (Fig. 6a),
presumptive MDR-TB cases (Fig. 6b) and confirmed
MDR-TB patients (Fig. 6c).
TB cases of all forms
In the absence of a national TB prevalence study, WHO
estimates that there were 61,880 (95% CI 40,040–88,400)
prevalent TB cases in the country in 2017 (Fig. 6a). Sur-
rogate markers of TB prevalence such as centralised
tracking of anti-TB drug distribution or universal
Fig. 3 Sample referral delays, MDR-TB surveillance programme, Madagascar, 2012–2017
Fig. 4 Diagnosed rifampicin monoresistance, isoniazid monoresistance and multidrug-resistance, MDR-TB surveillance programme,
Madagascar, 2012–2017
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healthcare digital system data were not available to cor-
roborate the WHO and NTP data in Madagascar. NTP
case notification data, NTP diagnosis algorithms and
NRLM diagnosis data were used to estimate the number
of smear-positive patients being evaluated at diagnostic
and treatment centres. Smear-positive to smear-negative
ratios in the diagnosed population were used to infer the
number of smear-negative patients being evaluated at
diagnostic and treatment centres. We estimate that
51,419 (95% CI 46,744–57,250) patients with active TB
disease accessed diagnostic and treatment centres. This
represents an estimated 10,461 (16.9%) of TB patients
going missing without any interaction with the health
system. A total of 35,339 (95% CI 35,124–35,570) were
appropriately diagnosed with TB. This was estimated
using Madagascar NTP notification data and calculated
average loss to follow-up rates, assuming those rates are
constant following diagnosis and until treatment com-
pletion. As per Madagascar NTP clinical management
data, 32,427 and 28,178 patients were, respectively,
registered for treatment and appropriately followed until
treatment completion. Madagascar’s NTP does not col-
lect post-treatment, long-term follow-up data for TB pa-
tients. The country’s overall retreatment rates and
literature data on the rates of early versus late relapse were
used to estimate that 27,996 (95% CI 27,774–28,108)
patients had successfully progressed towards 12–24
months recurrence-free survival.
Presumptive MDR-TB cases
Using the ratio of presumptive MDR-TB patients noti-
fied by the NTP and the total WHO number of preva-
lent cases, we estimate there were 3646 (95% CI 2258–
5437) cases of presumptive MDR-TB in Madagascar in
2017. Using the same estimation as for TB all forms,
3563 (95% CI 3197–4046) of those reached a TB diagno-
sis centre and 2485 (95% CI 2443–2540) were diagnosed
with TB and recognised as presumptive MDR-TB pa-
tients. Among these presumptive MDR-TB cases, only
610 (24.5%) had a sputum sample sent for testing in the
Table 3 MDR-TB patient characteristics, MDR-TB surveillance programme, Madagascar, 2012–2017
Presumptive MDR-TB MDR-TB Univariable logistic regression
n (%) n % (95% CI) Unadjusted OR (95% CI) p-value
Total 2391 (100.0) 89 3.7 (3.0–4.6) – –
Gender
Male 1620 (68.1) 60 3.7 (2.8–4.7) 1.00 (reference population)
Female 760 (31.9) 29 3.8 (2.6–5.4) 1.06 (0.67–1.67) 0.802
Median age (in years [range]) 40 [2–88] 40 [12–67] – – –
Previous treatment history
Relapse 1476 (61.7) 39 2.6 (1.9–3.6) 1.00 (reference population)
Failure 333 (13.9) 33 9.9 (6.9–13.6) 3.87 (2.39–6.28) < 0.001
Retreatment 243 (10.2) 4 1.6 (0.5–4.2) 0.58 (0.21–1.64) 0.304
Unknown 339 (14.2) 13 3.8 (2.1–6.5) 1.70 (0.90–3.24) 0.104
CI confidence interval, MDR-TB multidrug-resistant tuberculosis, OR odds ratio
Fig. 5 Geographic distribution of MDR-TB cases per region, MDR-TB surveillance programme, Madagascar, 2012–2017. a Referral rates of
presumptive MDR-TB cases. b MDR-TB patients’ absolute numbers. c MDR-TB incidence rate per 100,000 population
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NRLM and were thus appropriately enrolled in the
MDR-TB surveillance programme (Tables 1 and 2). Ac-
cording to NTP notification and clinical management
data, 2485 presumptive MDR-TB patients were diag-
nosed, 2257 were appropriately enrolled into treatment
and 1852 of those completed therapy. We estimate that
1670 (95% CI 1448–1782) were cured and recurrence-
free at 12–24months.
MDR-TB cases
Based on WHO estimates, a previous drug resistance
survey, capacity for DST and mono-rifampicin resistance
to multidrug-resistance ratios obtained from the NRLM
diagnosis and DST data, we estimate that there were 341
(95% CI 61–913) prevalent cases of MDR-TB in
Madagascar in 2017. Given the limited inclusion of smear-
negative patients in the MDR-TB surveillance programme,
Fig. 6 Cascade of care, Madagascar, 2017. a TB all forms. b Presumptive MDR-TB cases. c MDR-TB patients. Percentage represent the amount of
patients lost at every gap of the cascade of care (e.g. 17% of prevalent cases of TB all forms do not reach diagnostic and treatment centres and
26% of patients reaching diagnostic and treatment centres are not diagnosed)
Knoblauch et al. BMC Medicine          (2020) 18:173 Page 10 of 14
we evaluate that 224 (95% CI 170–330) patients reached
the diagnosis and treatment centres but only 24 (95% CI
22–27) of them were diagnosed with MDR-TB. According
to the 2017 diagnosis algorithm, only culture results were
considered for the diagnosis of MDR-TB. Hence, only 18
MDR-TB cases were effectively reported to the NTP and
correctly initiated for treatment. Importantly, due to the
previous algorithms used, 6 (25.0%) MDR-TB cases were
missed and left un- or inappropriately treated. Eight pa-
tients (33.3%) completed therapy and were declared as
cured. Finally, among treated patients, 6 (33.3%) were lost
to follow-up and 4 (22.2%) experienced a fatal outcome,
resulting in a mortality rate between 22.2% and 55.5%. No
information on long-term recurrence-free survival was
available. Hence, we assumed the 8 patients who had com-
pleted treatment have survived.
Discussion
The Madagascar MDR-TB epidemiology and cascade of
care were approximated using best available data, NTP
documentation and literature. Geospatial and cascade
approaches were used to understand the challenges of
MDR-TB control in the country and set the ground for
targeted control and elimination efforts.
The first gap in the cascade of care model pertaining
to prevalent MDR-TB cases that do not reach diagnostic
and treatment centres was estimated at 34.3%. In
Madagascar, access to healthcare is notoriously limited
as up to 60% of the population live in > 5 km distance to
a primary healthcare facility and 20% live in enclaved
areas [29]. The coverage for TB diagnostic and treat-
ment centres is even more bleak as only 219 of the 2563
primary facilities (8.5%) are diagnosing TB, which can
translate to distances of several days of walk to the near-
est diagnostic and treatment centre [29, 30]. Since
programme onset in 2012, the geographical coverage
and diagnostic and referral capacities of the MDR-TB
surveillance programme were gradually expanded. This
trend is continued beyond the study period, with an add-
itional 67 diagnostic and treatment centres trained to act
as collaborative centres until 2019. Notwithstanding sig-
nificant improvements, there remain large proportions
of the population without access to TB and MDR-TB
diagnosis and treatment, a major pitfall in disease con-
trol [31]. In addition, in contrary to the programme al-
gorithms, only about a fifth of presumptive MDR-TB
cases have been referred to the MDR-TB surveillance
programme. Furthermore, specific attention is warranted
for the referral of extrapulmonary TB cases where very
low rates were noted although national data suggests
that 21% of TB cases are extrapulmonary. This discrep-
ancy is probably a surrogate marker for the limited avail-
able resources of obtaining extrapulmonary clinical
samples in diagnostic and treatment centres. In
conclusion, both a continued geographical expansion of
the MDR-TB surveillance programme coverage and an
improvement of its current performance, including staff
awareness, training and supervision, are recommended.
The next marked gap in the modelled cascade occurs
between the amount of TB patients reaching diagnostic
facilities and those being effectively diagnosed with dis-
ease where marking losses of 26.0% (all forms of TB)
and 58.7% (MDR-TB) are observed. The current use of
smear microscopy as a first-line assay and the national
underuse of GeneXpert MTB/RIF platforms negatively
influence the diagnosis rates of both TB and MDR-TB
due to the lower sensitivity of microscopy [20, 32]. The
fact that this gap is markedly higher in the MDR-TB cas-
cade reflects the limited referral rates of smear-negative
presumptive MDR-TB patients for GeneXpert MTB/RIF
and culture reference testing within the MDR-TB sur-
veillance programme. Our GIS approach confirmed that
regions and diagnostic and treatment centres that ensure
access to DST for more presumptive MDR-TB cases are
finding more cases. Consequently, the approach was also
able to identify diagnostic and treatment centres that are
underperforming in terms of referral to the national
MDR-TB surveillance programme.
Universal access to DST is now recommended by
WHO, but results show that less than 1% of Malagasy TB
patients have access to any form of DST, which is consid-
erably below the global average estimate of 30% [33, 34].
Restricting DST to presumptive MDR-TB patients, as
done in Madagascar to date, results in patients with pri-
mary resistance cycling through at least one unsuccessful
treatment course before their resistance is detected. Ac-
cording to findings of the 2005–2006 national survey, pri-
mary resistance was found in 0.2% of TB patients [1].
However, in this study, most MDR-TB cases were treat-
ment failure cases, which could suggest that primary re-
sistance is higher than previously reported.
To date, access to GeneXpert MTB/RIF is limited and
requires referral of samples. These referrals are organised
by road transport through a service provider or individual
porters in areas not served by the service provider. With
an average of 30 days for sample referral in 2017, the re-
ferral system is exceeding the NTP’s targeted maximum of
5 days by far [18]. These delays might be partly respon-
sible for the high rate (17.6%) of failure to confirm TB on
culture on referred samples (Table 2) [1]. Other factors
causing this high rate might include (i) false positive smear
microscopy testing in the diagnosis and treatment centres,
(ii) presence of dead bacilli on initial smear microscopy
testing or (iii) culture contamination. However, available
data did not allow to test these hypotheses.
The benefits of strengthening referral systems on de-
lays and diagnosis rates have been demonstrated in other
low-income countries [35]. In Madagascar, innovative
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technologies such as drones were recently tested to ac-
celerate access to diagnosis and render TB care more
patient-centric by overcoming pertinent logistic barriers
on the last mile [36]. In addition, the country was
upscaling its GeneXpert MTB/RIF platform capacity
from 7 to 15 in 2019 and this expansion is expected to
help towards narrowing this gap in the cascade of care.
According to cascade estimates, 75.0% of all diagnosed
MDR-TB patients were initiated on treatment. The gap
between diagnosis and registration for treatment might
be explained by under-reporting, the loss of information
between the national TB laboratory and the NTP treat-
ment teams, and the fact that there were only four treat-
ment centres in Madagascar. Thus, patients have to
spend the 6 initial months of treatment in isolation po-
tentially far away from their homes, hence representing
a barrier to MDR-TB treatment access. However, ac-
cording to the NTP MDR-TB clinical management data,
all MDR-TB cases which were reported to the NTP were
initiated on treatment suggesting efficient procedures
and communication among the different actors, includ-
ing the patient.
The mortality rate in treated cases, accounting for un-
known outcomes in patients lost to follow-up, ranged
between 22.2% and 55.5% in treated cases that is higher
than the global average of 15.0% [37].
In Madagascar, the rate of MDR-TB among presump-
tive MDR-TB cases remained relatively stable over the
study period, ranging between 3.9% in 2013 and 4.4% in
2017. The national survey (2005–2006) found a MDR-
TB rate in presumptive MDR-TB cases of 3.4% [1]. The
cross-sectional nature of the survey is likely to give a
more precise picture of the true prevalence of MDR-TB
especially considering the suboptimal referral rate of
presumptive MDR-TB cases for DST in the surveillance
programme. This deficiency is diminishing the internal val-
idity of the surveillance data and potentially underestimates
the MDR-TB rate. Accordingly, WHO estimates the MDR-
TB rate in this group at 5.9% (2018) [33]. Conclusively, in
Madagascar, (i) improved compliance with NTP guidelines
and increased referral of presumptive MDR-TB patients for
reference DST will likely lead to an increase in MDR-TB
cases notifications, (ii) surveillance programme data is likely
to underestimate the true MDR-TB burden in the country
and (iii) a repetition of the national MDR-TB survey is war-
ranted to update the nationwide MDR-TB situation on pri-
mary and secondary resistance.
As of early 2018, Madagascar started to implement the
WHO-recommended 9-month ‘short’ treatment regimen
for MDR-TB and the here documented low levels of re-
sistance to fluoroquinolones and aminoglycosides bode
well for the implementation of this regimen. As new and
repurposed drugs, including bedaquiline and linezolid,
are now recommended as first-line agents for longer
MDR-TB regimens, laboratory capacity for susceptibility
testing to those drugs need to be developed in-country
[38]. Recent WHO guidelines for second-line drug
phenotypic testing and Madagascar’s implementation of
TB whole genome sequencing as a reference assay for
DST should ensure appropriate development of local
capacity for DST to those new and repurposed drugs
[39, 40].
In Madagascar, the absence of multiple drivers of the
MDR-TB epidemic represents a favourable starting pos-
ition for control and elimination. First, as described in
this study and previous reports including national drug
resistance surveys, the national incidence of MDR-TB
remains low compared to other low-income country set-
tings [33]. Second, the HIV infection prevalence in
Madagascar is low at 0.3% in 15–49-year-olds [12]. Evi-
dence supports an increased risk for TB acquisition, pro-
gression to active disease and transmission among HIV-
positive individuals as well as unfavourable outcomes
among MDR-TB and HIV co-infected patients [12, 41].
Third, the island status of the country excludes proxim-
ity to a high-prevalence MDR-TB setting and strongly
limits between-country mobility. Thus, no significant
introduction of MDR-TB is expected considering the
fact that migration is a main driver for infectious dis-
eases [42]. Even though at current stage there are no
strong indications that the MDR-TB situation will
change rapidly, a potential increase could occur if the
status quo for case finding and case holding is main-
tained. The increasing HIV rates are an alarming trend
that could have devastating effects on TB and MDR-TB
control [43].
Limitations
Our study has several limitations. The surveillance data
relies on routinely collected data with limited coverage
in a pre-defined high-risk group (i.e. presumptive MDR-
TB cases); hence, its ability to reflect the true MDR-TB
epidemiology in the general population is limited. The
cascade of care estimates rely on extensively collected
and aggregated data from the country’s NTP for all la-
boratory, notifications and treatment aspects of the TB
programme which led to reliable estimations of the cas-
cade. However, limitations on the calculations and esti-
mations of the different steps and gaps of the cascade of
care are described in Additional file 3: Appendix S3. In
addition, the reliance of MDR-TB diagnosis on smear
microscopy screening has led to significant uncertainty
and wide CIs around the number of MDR-TB patients
reaching TB diagnostic and treatment centres.
Conclusions
The findings presented here support the understanding
of the MDR-TB epidemiology and cascade of care in
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Madagascar. The data revealed pitfalls in TB and MDR-
TB control that need priority attention, including (i) an
expansion of the coverage of diagnostic and manage-
ment capacities, (ii) improved referral for presumptive
MDR-TB cases to the MDR-TB surveillance programme,
(iii) reduction of sample referral delays, (iv) improved
observation and monitoring of treatment and its out-
comes and (v) conduction of a representative national
drug resistance survey to elucidate on the true preva-
lence of MDR-TB in Madagascar [5]. Madagascar and
the international TB community are specifically chal-
lenged to enable access to state of the art TB diagnostics
and DST in conformity with international minimal stan-
dards for all Malagasy [44]. Together with programme
performance improvements suggested by this study,
MDR-TB control in Madagascar is achievable.
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